Showing results (261-270 of 313) with videos related to

Sort By:
Pageof 32
The Journal of Clinical Investigation|August 1, 1983
Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutationP E Daddona, B S Mitchell, H J Meuwissen, et al.
Journal of Toxicology and Environmental Health|January 1, 1984
Effects of coal dust and diesel exhaust on immune competence in ratsM S Mentnech, D M Lewis, S A Olenchock, et al.
Free Radical Research|March 18, 2014
Increase in insulin-induced relaxation of consecutive arterial segments toward the periphery: Role of vascular oxidative stateI A Szijártó, G A Molnár, E Mikolás, et al.
Thyroid : Official Journal of the American Thyroid Association|December 16, 1998
Papillary and follicular thyroid carcinoma metastatic to the skin: a case report and review of the literatureE A Koller, J B Tourtelot, H S Pak, et al.
The Journal of Cell Biology|July 14, 1999
Pex22p of Pichia pastoris, essential for peroxisomal matrix protein import, anchors the ubiquitin-conjugating enzyme, Pex4p, on the peroxisomal membraneA Koller, W B Snyder, K N Faber, et al.
International Journal of Immunopathology and Pharmacology|September 27, 2013
P16INK4A immunohistochemistry for detection of human papilloma virus-associated penile squamous cell carcinoma is superior to in-situ hybridizationK Aumayr, M Susani, R Horvat, et al.
Leukemia & Lymphoma|March 28, 1998
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemiaS M Kornblau, H Kantarjian, S O'Brien, et al.
Leukemia & Lymphoma|February 26, 1999
Primary myeloid leukemia presenting concomitantly with primary multiple myeloma: two cases and an update of the literatureC M Anderson, C E Bueso-Ramos, S A Wallner, et al.
Cancer|March 1, 1989
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Cancer|December 11, 1999
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemiaC A Koller, H M Kantarjian, E J Feldman, et al.
Pageof 32